|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas显示文摘 | NAGANE M ASAI A SHIBUI S | 1997 | Neurosurgery1997，41，2： | 1 |
| 2 | Applicaton of antisense ribonucleic acid complementary to 06-methylguanine-deoxyribonucleic acid rnethyltransferase messenger ribonucleic acid for therapy of malignant glionas 显示文摘 | Nangane M Asai A Shibui S | 1997 | Neurosurgery1997，41，2： | 1 |
| 3 | A novel method for development of malaria vaccines using full-length cDNA libraries显示文摘 | Shibui A Shiibashi T Nogami S | 2005 | Vaccine2005，23，34： | 1 |
| 4 | A novel method for development of malaria vaccines using full-length eDNA libraries显示文摘 | Shibui A Shiibashi T Nogami S | 2005 | Vaccine2005，23，34： | 1 |
| 5 | CD4(+) T cell re- sponse in early erythrocytic stage malaria: Plasmodium berghei infection in BALB/c and C57BL/6 mice显示文摘 | Shibui A Hozumi N Shiraishi C | 2009 | Parasitol Res2009，105，1： | 1 |
| 6 | The 5' ter minal oligopyrimidine tract of human elongation factor 1A-1 gene functions as a transcriptional initiator and produces a variable number of Us at the transcriptional level 显示文摘 | Shibui Nihei A Ohmori Y Yoshida K etal | 2003 | Gene2003，311，： | 1 |
| 7 | Effect of long-term nitrate treatment on cardiac events in patients with vasospastic angina 显示文摘 | Kosugi M Nakagomi A Shibui T | 2011 | Circ J2011，75，9： | 1 |
| 8 | Expression pattern of chemoresistance-related for proper selection of anticancer drugs显示文摘 | Nagane M Asai A Shibui S | 1999 | Jpa J Clin Oncol1999，29，1： | 1 |
| 9 | Expression pattern of chemoresistance-related genes in human malignant brain tumors:a working knowledge for proper selection of anticancer drugs显示文摘 | Nagane M Asai A Shibui S | 1999 | Jpn J Clin Oncol1999，29，11： | 1 |
| 10 | Application of antisense ribonucleic acid complementary to 06 - Methylguanine - deoxyibonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gJiomas显示文摘 | Nagane M Asai A Shibui S | 1997 | Neurosurgery1997，41，2： | 1 |
| 11 | Granuloms and crypto coccosis显示文摘 | Shibuys K Hirata A Omuta J | 2005 | J infect chemother2005，11，11： | 1 |
| 12 | Expression pattern of chemoresistance related for proper selection of anticancer drugs显示文摘 | Nagane M Asai A Shibui S | 1999 | Jpa J Clin Oncol1999，29，1： | 1 |
| 13 | Apllication of antisense ribonucleic acid complementary to O6-methylguanine -deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of maliglant glionas显示文摘 | Yoshinaga M Asai A Shibui S | 1997 | Neurosurgery1997，41，2： | 1 |
| 14 | Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)显示文摘Objectives: Glioblastoma(GBM) is one of the worst cancers in terms of prognosis.Standard therapy consists of resection with concomitant chemoradiotherapy.Resistance to nimustine hydrochloride(ACNU),an alkylating agent,has been linked to methylguanine DNA methyltransferase(MGMT).Daily administration of procarbazine(PCZ) has been reported to decrease MGMT activity.This study investigated the efficacy of ACNU + PCZ compared to ACNU alone for GBM and anaplastic astrocytoma(AA).Methods: Patients(20-69 years) who had newly diagnosed AA and GBM were randomly assigned to receive radiotherapy with ACNU alone or with ACNU + PCZ.The primary endpoint was overall survival(OS).This was designed as a phase Ⅱ/Ⅲ trial with a total sample size of 310 patients and was registered as UMIN-CTR C000000108.Results: After 111 patients from 19 centers in Japan were enrolled,this study was terminated early because temozolomide was newly approved in Japan.The median OS and median progression-free survival(PFS) with ACNU alone(n = 55) or ACNU + PCZ(n = 56) in the intention-to-treat population were 27.4 and 22.4 months(P = 0.75),and 8.6 and 6.9 months,respectively.The median OS and median PFS of the GBM subgroup treated with ACNU alone(n = 40) or ACNU + PCZ(n = 41) were 19.0 and 19.5 months,and 6.2 and 6.3 months,respectively.Grade 3/4 hematologic adverse events occurred in more than 40% of patients in both arms,and 27% of patients discontinued treatment because of adverse events.Conclusions: The addition of PCZ to ACNU was not beneficial,in comparison with ACNU alone,for patients with newly diagnosed AA and GBM. | Shibui S Narita Y Mizusawa J Beppu T Ogasawara K Sawamura Y Kobayashi H Nishikawa R Mishima K Muragaki Y Maruyama T Kuratsu J Nakamura H Kochi M Minamida Y Yamaki T Kumabe T Tominaga T Kayama T Sakurada K Nagane M Kobayashi K Nakamura H Ito T Yazaki T Sasaki H Tanaka K Takahashi H Asai A Todo T Wakabayashi T Takahashi J Takano S Fujimaki T Sumi M Miyakita Y Nakazato Y Sato A Fukuda H Nomura K | 2013 | 中国神经肿瘤杂志2013，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员